Breaking News, Financial News

Financial Report: Genentech 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech 2Q Revenues: $3.2 billion (+7%) 2Q Earnings: $782 million (+5%) YTD Revenues: $6.3 billion (+7%) YTD Earnings: $1.8 billion (+21%) Comments: Rituxan sales were $651 million in the quarter (+12%). Avastin sales were $650 million (+15%). Herceptin sales were $338 million (+3%). Tarceva sales were $119 million (+17%). Sales in the market reached $2.4 billion (+9%). Royalty revenue in the quarter was up 30% to $629 million primarily due to growth in ex-U.S. sales of the company&#...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters